Piramal Pharma Ltd

Piramal Pharma Limited's manufacturing facility in Morpeth, UK, was inspected by the US FDA for Good Manufacturing Practices (GMP) between September 3rd and September 11th, 2026. The inspection resulted in the issuance of a Form-483 with seven observations. These observations pertain to enhancements in the company's practices, procedures, and documentation. Piramal Pharma is actively working on a comprehensive response to be submitted to the US FDA within the designated timeframe, reaffirming its commitment to maintaining high compliance standards.

Piramal Pharma Ltd has received an ESG Rating of 65 for FY 2025-26 from NSE Sustainability Ratings and Analytics Limited. This rating marks an improvement from the previous score of 64, reflecting the company's sustained commitment to environmental, social, and governance principles. Notably, NSE Sustainability independently assigned this rating based on publicly available data, without any prior engagement with Piramal Pharma. The company has also made this information available on its website.

Deutsche Bank AG, Mumbai Branch, acting as the onshore security agent for CA Alchemy Investments, has filed a disclosure under SEBI's Takeover Regulations. This update concerns the re-creation of a pledge over 98,400,000 equity shares of Piramal Pharma Limited, representing 7.39% of the total issued and paid-up share capital. Following this re-creation, Deutsche Bank AG holds a total pledge over 238,663,700 equity shares, amounting to 17.93% of the company's issued and paid-up share capital. The bank clarifies it holds no beneficial interest in these shares, acting solely as a pledgee.

Piramal Pharma Limited (PPL) has released its Sustainability Report for the financial year 2025-26. The report details the company's non-financial performance across Environment, Social, and Governance (ESG) pillars. Key focus areas for FY26 included accelerating energy efficiency, increasing renewable energy use, strengthening circular economy practices, advancing water conservation, and expanding community programs in education and skill development. The report also highlights renewed attention on governance foundations, including embedding ethical practices and structured risk assessments. PPL has prepared this report in accordance with GRI Universal Standards 2021 and aligned with UN SDGs, covering its three business units: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and Piramal Consumer Healthcare (PCH).

Piramal Pharma Ltd (PPL) has completed the acquisition of an additional 1,46,400 equity shares in Yapan Bio Private Limited for approximately ₹76 crores. This acquisition increases PPL's shareholding in Yapan from 33.33% to 74.00%, transforming Yapan from an associate company into a subsidiary. Yapan, a CDMO specializing in vaccines and biologics, reported revenues of ₹26.91 crores, ₹54.40 crores, and ₹26.34 crores for FY2024, FY2025, and FY2026, respectively. This strategic move integrates Yapan's large molecule capabilities into PPL's offerings, enhancing its ability to develop and scale complex biologic therapies.

Deutsche Bank AG, acting as the onshore security agent, has disclosed the release of 98,400,000 equity shares of Piramal Pharma Limited. These released shares constitute 7.39% of the total issued and paid-up share capital. This action is part of a 'Permitted Sale Transaction' under a facility agreement. Following this release, Deutsche Bank continues to hold a pledge over 140,263,700 equity shares, representing 10.54% of the company's share capital. The disclosure is made under SEBI's Takeover Regulations.

Piramal Pharma Ltd has announced the exercise of its call option to acquire an additional 41% equity stake in Yapan Bio Private Limited, an associate company. This proposed transaction will increase Piramal Pharma's shareholding in Yapan from 33.33% to approximately 74%, thereby making Yapan a subsidiary. Yapan Bio specializes in process development and GMP manufacturing for vaccines and biologics. The final terms, including acquisition consideration and effective date, are yet to be finalized, and further disclosures will be made upon completion of definitive documentation.

Piramal Pharma Ltd has announced the resumption of operations at its manufacturing facilities in Ahmedabad, Gujarat, which were temporarily suspended due to heavy rainfall and flooding. While limited restoration activities are ongoing in certain sections, substantially all areas are now operational. The company has completed a preliminary assessment of the impact on its assets and operations and has initiated an insurance claim process. Based on current assessments, Piramal Pharma does not anticipate any material impact on its overall operations or financial performance.

Piramal Pharma Limited announced its Q1 FY27 results, reporting a 17% year-on-year increase in consolidated revenue from operations to ₹2,270 Crores. EBITDA saw a significant surge of 72% to ₹285 Crores, with EBITDA margins expanding by 400 basis points to 12.5%. This growth was driven by strong performance across all three business segments: CDMO, Complex Hospital Generics (CHG), and Consumer Healthcare (PCH). The company highlighted improved operating leverage, capacity utilization, and pricing discipline as key factors for margin expansion. The Sellersville facility in the US also received a positive Establishment Inspection Report from the US FDA.

Piramal Pharma Ltd announced its unaudited financial results for the first quarter of FY27, ended June 30, 2026. The Board of Directors approved the standalone and consolidated financial results. The company also confirmed that limited review reports by the statutory auditors have been enclosed. These results will be published in newspapers as per SEBI Listing Regulations and are also available on the company's website. The Board meeting commenced at 5:30 pm and concluded at 8:30 pm.